239 related articles for article (PubMed ID: 28119265)
1. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival.
Yu XZ; Guo ZY; Di Y; Yang F; Ouyang Q; Fu DL; Jin C
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):104-109. PubMed ID: 28119265
[TBL] [Abstract][Full Text] [Related]
2. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
[TBL] [Abstract][Full Text] [Related]
3. The role of SPARC expression in pancreatic cancer progression and patient survival.
Gundewar C; Sasor A; Hilmersson KS; Andersson R; Ansari D
Scand J Gastroenterol; 2015; 50(9):1170-4. PubMed ID: 25765175
[TBL] [Abstract][Full Text] [Related]
4. Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome.
Byrling J; Sasor A; Nilsson J; Said Hilmersson K; Andersson R; Andersson B
Scand J Gastroenterol; 2020 Jun; 55(6):725-731. PubMed ID: 32543919
[No Abstract] [Full Text] [Related]
5. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
6. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Yuasa Y; Kondo N; Ohge H; Sueda T
J Am Coll Surg; 2010 Aug; 211(2):196-204. PubMed ID: 20670857
[TBL] [Abstract][Full Text] [Related]
7. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis.
Asaoka T; Miyamoto A; Maeda S; Hama N; Tsujie M; Ikeda M; Sekimoto M; Nakamori S
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):75-80. PubMed ID: 29428109
[TBL] [Abstract][Full Text] [Related]
8. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer metastatic to a limited number of lymph nodes has no impact on outcome.
Baldwin S; Kukar M; Gabriel E; Attwood K; Wilkinson N; Hochwald SN; Kuvshinoff B
HPB (Oxford); 2016 Jun; 18(6):523-8. PubMed ID: 27317957
[TBL] [Abstract][Full Text] [Related]
10. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.
John BJ; Naik P; Ironside A; Davidson BR; Fusai G; Gillmore R; Watkins J; Rahman SH
HPB (Oxford); 2013 Sep; 15(9):674-80. PubMed ID: 23458477
[TBL] [Abstract][Full Text] [Related]
11. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.
Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Bui JL; Yuan C; Qian ZR; Babic A; Da Silva A; Nowak JA; Khalaf N; Brais LK; Welch MW; Zellers CL; Ng K; Chang DT; Miksad RA; Bullock AJ; Tseng JF; Swanson RS; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Hornick JL; Ogino S; Fuchs CS; Hezel AF; Koong AC; Wolpin BM
Br J Cancer; 2017 Dec; 117(12):1874-1882. PubMed ID: 28982112
[TBL] [Abstract][Full Text] [Related]
12. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease.
Williams JL; Nguyen AH; Rochefort M; Muthusamy VR; Wainberg ZA; Dawson DW; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
J Surg Oncol; 2015 Sep; 112(4):396-402. PubMed ID: 26303811
[TBL] [Abstract][Full Text] [Related]
14. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
[TBL] [Abstract][Full Text] [Related]
15. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
16. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma.
Bhatti I; Peacock O; Awan AK; Semeraro D; Larvin M; Hall RI
World J Surg; 2010 Apr; 34(4):768-75. PubMed ID: 20052471
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study.
Zheng ZJ; Wang MJ; Tan CL; Chen YH; Ping J; Liu XB
Medicine (Baltimore); 2020 Feb; 99(8):e19327. PubMed ID: 32080152
[TBL] [Abstract][Full Text] [Related]
18. SPARC expression in desmoplastic and non desmoplastic pancreatic carcinoma and cholangiocarcinoma.
Khetan K; Baloda V; Sahoo RK; Vishnubhathla S; Yadav R; Saraya A; Sharma A; Gupta SD; Das P
Pathol Res Pract; 2019 Dec; 215(12):152685. PubMed ID: 31727501
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas.
Fujita T; Nakagohri T; Gotohda N; Takahashi S; Konishi M; Kojima M; Kinoshita T
Pancreas; 2010 Jan; 39(1):e48-54. PubMed ID: 19910836
[TBL] [Abstract][Full Text] [Related]
20. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
